REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/17/2025
Back to search
Official data from USPTO
DIGITOME
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DIGITOME
ST13
US500000088118686Class
42, 44
Filing
88118686
Registration
6010838
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
03/17/2025
Trademark type
Word
Nice classes
42, 44
Filing date
09/15/2018
Registration date
03/17/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/17/2020
Last transaction
03/17/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
10/11/2017
First use in commerce
10/11/2017
Drawing code
4
Owner type
03
Owner location
Palo Alto, CA
Examiner
MURRAY, TY
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Medable, Inc.
Representatives
Omar M. Wadhwa Cesari and McKenna, LLP
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Software as a service (SAAS) serviceshosting software for use by others for use for disease progression prediction; Software as a service (SAAS) serviceshosting software for use by others for use for medical status assessment; Software as a service (SAAS) serviceshosting software for use by others for use for overall health assessment; Software as a service (SAAS) serviceshosting software for use by others for use to determine effective therapies and medications; Software as a service (SAAS) serviceshosting software for use by others for use to make medical decisions; Application service provider (ASP) featuring software for use in the collectionprocessingstorage and exchange of human health and disease data; Application service provider (ASP) featuring software for use in the collectionprocessingstorage and exchange of genetic data; Application service provider (ASP) featuring software for use to derive insights and or understanding about human health and disease.; Application service provider (ASP) featuring software for use for predictive analytics; Application service provider (ASP) featuring software for use for disease progression prediction; Application service provider (ASP) featuring software for use for medical status assessment; Application service provider (ASP) featuring software for use for overall health assessment; Application service provider (ASP) featuring software for use to determine effective therapies and medications; Application service provider (ASP) featuring software for use to make medical decisions; Application service provider (ASP) featuring software for use to assist in overall medical and therapeutic decision making; Conducting clinical trials for others; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Medical and scientific researchconducting clinical trials for others; Platform as a service (PAAS) featuring computer software platforms for in the collectionprocessingstorage and exchange of human health and disease data; Platform as a service (PAAS) featuring computer software platforms for in the collectionprocessingstorage and exchange of genetic data; Platform as a service (PAAS) featuring computer software platforms for to derive insights and or understanding about human health and disease.; Platform as a service (PAAS) featuring computer software platforms for for predictive analytics; Platform as a service (PAAS) featuring computer software platforms for for disease progression prediction; Platform as a service (PAAS) featuring computer software platforms for for medical status assessment; Platform as a service (PAAS) featuring computer software platforms for for overall health assessment; Platform as a service (PAAS) featuring computer software platforms for to determine effective therapies and medications; Platform as a service (PAAS) featuring computer software platforms for to make medical decisions; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Class 44
Health care servicesproviding a database in the field of disease detection and management information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Health care servicesproviding a database in the field of disease therapy information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes
Publications
History of USPTO decisions and trademark events.
29 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/23/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/23/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
03/17/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/31/2019
PUBO
PUBLISHED FOR OPPOSITION
12/31/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/11/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/04/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/26/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
11/26/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/26/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
11/26/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/26/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/06/2019
GNRT
NON-FINAL ACTION E-MAILED
10/06/2019
CNRT
NON-FINAL ACTION WRITTEN
10/06/2019
NREV
NOTICE OF REVIVAL - E-MAILED
09/30/2019
PETG
PETITION TO REVIVE-GRANTED
09/30/2019
PROA
TEAS PETITION TO REVIVE RECEIVED
09/30/2019
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
07/30/2019
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
07/30/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/01/2019
GNRT
NON-FINAL ACTION E-MAILED
01/01/2019
CNRT
NON-FINAL ACTION WRITTEN
01/01/2019
DOCK
ASSIGNED TO EXAMINER
12/27/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/22/2018
NWAP
NEW APPLICATION ENTERED
09/19/2018
Continuous trademark protection
Get notified about every new filing that threatens DIGITOME or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.